Loading...
Please wait, while we are loading the content...
Similar Documents
Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2
| Content Provider | MDPI |
|---|---|
| Author | Gagliardi, Maria Ashizawa, Ana Tari |
| Copyright Year | 2022 |
| Description | The B-cell lymphoma 2 (Bcl-2) family, comprised of pro- and anti-apoptotic proteins, regulates the delicate balance between programmed cell death and cell survival. The Bcl-2 family is essential in the maintenance of tissue homeostasis, but also a key culprit in tumorigenesis. Anti-apoptotic Bcl-2, the founding member of this family, was discovered due to its dysregulated expression in non-Hodgkin’s lymphoma. Bcl-2 is a central protagonist in a wide range of human cancers, promoting cell survival, angiogenesis and chemotherapy resistance; this has prompted the development of Bcl-2-targeting drugs. Antisense oligonucleotides (ASO) are highly specific nucleic acid polymers used to modulate target gene expression. Over the past 25 years several Bcl-2 ASO have been developed in preclinical studies and explored in clinical trials. This review will describe the history and development of Bcl-2-targeted ASO; from initial attempts, optimizations, clinical trials undertaken and the promising candidates at hand. |
| Starting Page | 97 |
| e-ISSN | 19994923 |
| DOI | 10.3390/pharmaceutics14010097 |
| Journal | Pharmaceutics |
| Issue Number | 1 |
| Volume Number | 14 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-01-01 |
| Access Restriction | Open |
| Subject Keyword | Pharmaceutics Antisense Oligonucleotides (aso) Apoptosis Bcl-2 Exosomes Liposomes Microrna (mirna) Small Interfering Rna (sirna) Venetoclax |
| Content Type | Text |
| Resource Type | Article |
